Abdominal Imaging

, Volume 38, Issue 6, pp 1431–1446

Imaging treated prostate cancer

  • P. J. L. De Visschere
  • H. A. Vargas
  • P. Ost
  • G. O. De Meerleer
  • G. M. Villeirs
Article
  • 538 Downloads

Abstract

In patients with a clinical suspicion of recurrence after treatment for prostate cancer, imaging can be used to distinguish between local recurrence and metastatic disease. Multiparametric magnetic resonance imaging (mpMRI) of the prostate may be a valuable imaging modality for the detection and localization of local recurrence in patients treated for prostate cancer. In mpMRI, morphological T2-weighted images are combined with functional MRI techniques including diffusion-weighted imaging, dynamic contrast-enhanced imaging, and magnetic resonance spectroscopic imaging to improve accuracy. In this paper, the current status of imaging techniques used to detect and to localize tumor recurrence in patients treated for prostate cancer will be reviewed, with emphasis on mpMRI for local prostate cancer recurrence.

Keywords

Prostate Imaging Cancer Recurrence Multiparametric MRI 

References

  1. 1.
    Siegel R, Naishadham D, Jemal A (2012) Cancer statistics 2012. CA Cancer J Clin 62(1):10–29PubMedGoogle Scholar
  2. 2.
    Kupelian PA, Potters L, Khuntia D, et al. (2004) RP, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys 58:25–33PubMedGoogle Scholar
  3. 3.
    Grossfeld GD, Li YP, Lubeck DP, et al. (2002) Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. J Urol 168(2):530–535PubMedGoogle Scholar
  4. 4.
    Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR (2008) Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 112(2):307–314PubMedGoogle Scholar
  5. 5.
    Bolla M, Collette L, Blank L, et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360(9327):103–106PubMedGoogle Scholar
  6. 6.
    Mottet N, Bellmunt J, Bolla M, et al. (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59(4):572–583PubMedGoogle Scholar
  7. 7.
    The Medical Research Council Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostatic cancer initial results of the Medical Research Council Trial. Br J Urol 79(2):235–246Google Scholar
  8. 8.
    D’Amico AV, Whittington R, Malkowicz SB, et al. (2002) Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95(2):281–286PubMedGoogle Scholar
  9. 9.
    Kuban DA, Thames HD, Levy LB, et al. (2003) Long-term multi-institutional analysis of stage T1–T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57(4):915–928PubMedGoogle Scholar
  10. 10.
    Anscher MS, Clough R, Dodge R (2000) Radiotherapy for a rising prostate-specific antigen after RP: the first 10 years. Int J Radiat Oncol Biol Phys 48:369–375PubMedGoogle Scholar
  11. 11.
    Olsson AY, Bjartell A, Lilja H, Lundwall A (2005) Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. Int J Cancer 113:290–297PubMedGoogle Scholar
  12. 12.
    Stephenson AJ, Scardino PT, Kattan MW, et al. (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after RP. J Clin Oncol 25:2035–2041PubMedGoogle Scholar
  13. 13.
    MacDonald OK, Schild SE, Vora S, et al. (2004) Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after RP: do outcomes differ? Urology 64:760–764PubMedGoogle Scholar
  14. 14.
    Koppie TM, Grossfeld GD, Nudell DM, Weinberg VK, Carroll PR (2001) Is anastomotic biopsy necessary before radiotherapy after RP? J Urol 166:111–115PubMedGoogle Scholar
  15. 15.
    Beresford MJ, Gillatt D, Benson RJ, Ajithkumar T (2010) A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin Oncol (R Coll Radiol) 22(1):46–55Google Scholar
  16. 16.
    Heidenreich ABJ, Bolla M, Joniau S, et al. (2011) Treatment of biochemical failure after treatment with curative intent Guidelines on Prostate Cancer. EAU Guidelines Office, Arnhem. pp 121–133Google Scholar
  17. 17.
    Scattoni V, Montorsi F, Picchio M, et al. (2004) Diagnosis of local recurrence after radical prostatectomy. BJU Int 93(5):680–688PubMedGoogle Scholar
  18. 18.
    Kuban DA, Levy LB, Potters L, et al. (2006) Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 65:1487–1493PubMedGoogle Scholar
  19. 19.
    Cheung R, Tucker SL, Lee AL, et al. (2005) Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 61:14–19PubMedGoogle Scholar
  20. 20.
    Kanai K, Nakashima J, Sugawara A, et al. (2009) Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer. Int J Clin Oncol 14:502–506PubMedGoogle Scholar
  21. 21.
    Sheinbein C, Teh BS, Mai WY, et al. (2010) Prostate-specific antigen bounce after intensity-modulated radiotherapy for prostate cancer. Urology 76(3):728–733Google Scholar
  22. 22.
    De Visschere PJ, De Meerleer GO, Fütterer JJ, Villeirs GM (2010) Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am J Roentgenol 194(6):1427–1433PubMedGoogle Scholar
  23. 23.
    Vargas HA, Wassberg C, Akin O, Hricak H (2012) MR imaging of treated prostate cancer. Radiology 262(1):26–42PubMedGoogle Scholar
  24. 24.
    Wu LM, Xu JR, Gu HY, et al. (2013) Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. Clin Oncol (R Coll Radiol). doi:10.1016/j.clon.2012.11.010
  25. 25.
    Bolla M, van Poppel H, Collette L, et al. (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366(9485):572–578Google Scholar
  26. 26.
    Swanson GP, Hussey MA, Tangen CM, et al. (2007) Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25(16):2225–2229PubMedGoogle Scholar
  27. 27.
    Zietman AL, DeSilvio ML, Slater JD, et al. (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294(10):1233–1239PubMedGoogle Scholar
  28. 28.
    Kuban DA, Tucker SL, Dong L, et al. (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67–74PubMedGoogle Scholar
  29. 29.
    Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. (2008) Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72(4):980–988PubMedGoogle Scholar
  30. 30.
    Zelefsky MJ, Reuter VE, Fuks Z, Scardino P, Shippy A (2008) Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol. 179(4):1368–1373; discussion 1373Google Scholar
  31. 31.
    Crook JM, Malone S, Perry G, et al. (2009) Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial. Cancer 115(3):673–679PubMedGoogle Scholar
  32. 32.
    Stone NN, Stock RG, White I, Unger P (2007) Patterns of local failure following prostate brachytherapy. J Urol 177(5):1759–1763PubMedGoogle Scholar
  33. 33.
    Zietman AL, Bae K, Slater JD, et al. (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95–09. J Clin Oncol 28(7):1106–1111PubMedGoogle Scholar
  34. 34.
    National Comprehensive Cancer Network (NCCN) (2011) NCCN clinical practice guidelines in oncology. Prostate Cancer. Version 2.2011. www.nccn.org. Accessed 20 Feb 2013
  35. 35.
    Lughezzani G, Briganti A, Karakiewicz PI, et al. (2010) Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol 58(5):687–700PubMedGoogle Scholar
  36. 36.
    Nguyen PL, D’Amico AV, Lee AK, Suh WW (2007) Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 110(7):1417–1428PubMedGoogle Scholar
  37. 37.
    Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B (2008) A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol 179(3):906–910PubMedGoogle Scholar
  38. 38.
    Ward JF, Moul JW (2005) Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol 15(3):181–186PubMedGoogle Scholar
  39. 39.
    Kane CJ, Amling CL, Johnstone PA, et al. (2003) Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61(3):607–611PubMedGoogle Scholar
  40. 40.
    Giovacchini G, Picchio M, Coradeschi E, et al. (2009) Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 37(2):301–309PubMedGoogle Scholar
  41. 41.
    Picchio M, Messa C, Landoni C, et al. (2003) Value of [11C]choline–positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 169(4):1337–1340PubMedGoogle Scholar
  42. 42.
    Reske SN, Blumstein NM, Glatting G (2008) [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 35(1):9–17PubMedGoogle Scholar
  43. 43.
    Rinnab L, Simon J, Hautmann RE, et al. (2009) [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol 27(5):619–625PubMedGoogle Scholar
  44. 44.
    Heesakkers RA, Hovels AM, Jager GJ, et al. (2008) MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 9(9):850–856PubMedGoogle Scholar
  45. 45.
    Harisinghani MG, Barentsz J, Hahn PF, et al. (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348(25):2491–2499PubMedGoogle Scholar
  46. 46.
    Eiber M, Beer AJ, Holzapfel K, et al. (2010) Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol 45(1):15–23PubMedGoogle Scholar
  47. 47.
    Picchio M, Briganti A, Fanti S, et al. (2011) The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 59(1):51–60PubMedGoogle Scholar
  48. 48.
    Singh D, Yi WS, Brasacchio RA, et al. (2004) Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys 58(1):3–10PubMedGoogle Scholar
  49. 49.
    Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10PubMedGoogle Scholar
  50. 50.
    Chang BK, Timmerman RD (2007) Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol 30(6):637–644PubMedGoogle Scholar
  51. 51.
    King CR, Kapp DS (2008) Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys 71(2):346–350PubMedGoogle Scholar
  52. 52.
    Cellini N, Morganti AG, Mattiucci GC, et al. (2002) Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 53(3):595–599PubMedGoogle Scholar
  53. 53.
    Pucar D, Hricak H, Shukla-Dave A, et al. (2007) Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 69:62–69PubMedGoogle Scholar
  54. 54.
    Krämer S, Görich J, Gottfried HW, et al. (1997) Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 70(838):995–999PubMedGoogle Scholar
  55. 55.
    Breeuwsma AJ, Pruim J, van den Bergh AC, et al. (2010) Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. Int J Radiat Oncol Biol Phys 77(1):160–164PubMedGoogle Scholar
  56. 56.
    Panebianco V, Sciarra A, Lisi D (2012) Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol 81(4):700–708PubMedGoogle Scholar
  57. 57.
    Miralbell R, Vees H, Lozano J, et al. (2007) Endorectal MRI assessment of local relapse after surgery for prostate cancer: a model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure. Int J Radiat Oncol Biol Phys 67(2):356–361PubMedGoogle Scholar
  58. 58.
    Barentsz JO, Richenberg J, Clements R, et al. (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22(4):746–757PubMedGoogle Scholar
  59. 59.
    Schiebler ML, Schnall MD, Pollack HM, et al. (1993) Current role of MR imaging in the staging of adenocarcinoma of the prostate. Radiology 189:339–352PubMedGoogle Scholar
  60. 60.
    Villeirs GM, De Meerleer GO (2007) Magnetic resonance imaging (MRI) anatomy of the prostate and application of MRI in radiotherapy planning. Eur J Radiol 63:361–368PubMedGoogle Scholar
  61. 61.
    Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H (2008) MR imaging of the prostate in clinical practice. Magma 21:379–392PubMedGoogle Scholar
  62. 62.
    Kim JK, Jang YJ, Cho G (2009) Multidisciplinary functional MR imaging for prostate cancer. Korean J Radiol 10:535–551PubMedGoogle Scholar
  63. 63.
    Sella T, Pucar D (2009) Imaging recurrent prostate cancer, chap 12. In: Hricak H, Scardino PT (eds) Contemporary issues in cancer imaging: prostate cancer. Cambridge University Press, New York, pp 195–222Google Scholar
  64. 64.
    Kim CK, Park BK, Park W, Kim SS (2010) Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience. Abdom Imaging 35(2):246–252Google Scholar
  65. 65.
    Van As N, Charles-Edwards E, Jackson A, et al. (2008) Correlation of diffusion-weighted MRI with whole mount RP specimens. Br J Radiol 81:456–462PubMedGoogle Scholar
  66. 66.
    Casciani E, Polettini E, Carmenini E, et al. (2008) Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after RP. AJR Am J Roentgenol 190:1187–1192PubMedGoogle Scholar
  67. 67.
    Seitz M, Shukla-Dave A, Bjartell A, et al. (2009) Functional magnetic resonance imaging in prostate cancer. Eur Urol 55:801–814PubMedGoogle Scholar
  68. 68.
    Ocak I, Bernardo M, Metzger G, et al. (2007) Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol 189:849PubMedGoogle Scholar
  69. 69.
    Futterer JJ, Heijmink SW, Scheenen TW, et al. (2006) Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 241:449–458PubMedGoogle Scholar
  70. 70.
    Haider MA, Chung P, Sweet J, et al. (2008) Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 70:425–430PubMedGoogle Scholar
  71. 71.
    Costello LC, Franklin RB (2000) The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy. Oncology 59:269–282PubMedGoogle Scholar
  72. 72.
    Kavanagh JP (1985) Sodium, potassium, calcium, magnesium, zinc, citrate and chloride content of human prostatic and seminal fluid. J Reprod Fertil 75:35–41PubMedGoogle Scholar
  73. 73.
    Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM (2001) Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 61:3599–3603PubMedGoogle Scholar
  74. 74.
    Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM (2006) Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm 3:496–506PubMedGoogle Scholar
  75. 75.
    Kurhanewicz J, Vigneron D, Hricak H, et al. (1996) Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7-cm³) spatial resolution. Radiology 198:795–805PubMedGoogle Scholar
  76. 76.
    Umbehr M, Bachmann LM, Held U, et al. (2009) Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Eur Urol 55:575–591PubMedGoogle Scholar
  77. 77.
    Allen SD, Thompson A, Sohaib SA (2008) The normal post-surgical anatomy of the male pelvis following RP as assessed by magnetic resonance imaging. Eur Radiol 18:1281–1291PubMedGoogle Scholar
  78. 78.
    Wasserman NF, Kapoor DA, Hildebrandt WC, et al. (1992) Transrectal US in evaluation of patients after RP. Part I. Normal postoperative anatomy. Radiology 185:361–366PubMedGoogle Scholar
  79. 79.
    Silverman JM, Krebs TL (1997) MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone RP. AJR Am J Roentgenol 168:379–385PubMedGoogle Scholar
  80. 80.
    Sella T, Schwartz LH, Swindle PW, et al. (2004) Suspected local recurrence after RP: endorectal coil MR imaging. Radiology 231:379–385PubMedGoogle Scholar
  81. 81.
    Cirillo S, Petracchini M, Scotti L, et al. (2009) Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following RP using T2-weighted and contrast-enhanced imaging. Eur Radiol 19:761–769PubMedGoogle Scholar
  82. 82.
    Foster LS, Jajodia P, Fournier GJr, et al. (1993) The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following RP. J Urol 149:1024–1028PubMedGoogle Scholar
  83. 83.
    Salomon CG, Flisak ME, Olson MC, et al. (1993) RP: transrectal sonographic evaluation to assess for local recurrence. Radiology 189:713–719PubMedGoogle Scholar
  84. 84.
    Sella T, Schwartz LH, Hricak H (2006) Retained seminal vesicles after RP: frequency, MRI characteristics, and clinical relevance. AJR Am J Roentgenol 186:539–546PubMedGoogle Scholar
  85. 85.
    Sciarra A, Panebianco V, Salciccia S, et al. (2008) Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after RP for prostate cancer. Eur Urol 54:589–600PubMedGoogle Scholar
  86. 86.
    Rouviere O, Vitry T, Lyonnet D (2009) Imaging of prostate cancer local recurrences: why and how? Eur Radiol 20(5):1254–1266Google Scholar
  87. 87.
    Giannarini G, Nguyen DP, Thalmann GN, Thoeny HC (2012) Diffusion-weighted magnetic resonance imaging detects local recurrence after radical prostatectomy: initial experience. Eur Urol 61(3):616–620PubMedGoogle Scholar
  88. 88.
    Coakley FV, Hricak H, Wefer AE, et al. (2001) Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes. Radiology 219:817–821PubMedGoogle Scholar
  89. 89.
    Sheaff MT, Baithun SI (1997) Effects of radiation on the normal prostate gland. Histopathology 30:341–348PubMedGoogle Scholar
  90. 90.
    Pucar D, Shukla-Dave A, Hricak H, et al. (2005) Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 236:545–553PubMedGoogle Scholar
  91. 91.
    Coakley FV, Teh HS, Qayyum A, et al. (2004) Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233:441–448PubMedGoogle Scholar
  92. 92.
    Cellini N, Morganti AG, Mattiucci GC, et al. (2002) Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 53:595–599PubMedGoogle Scholar
  93. 93.
    Rouviere O, Valette O, Grivolat S, et al. (2004) Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor-correlation with biopsy findings. Urology 63:922–927PubMedGoogle Scholar
  94. 94.
    Menard C, Smith IC, Somorjai RL, et al. (2001) Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity. Int J Radiat Oncol Biol Phys 50:317–323PubMedGoogle Scholar
  95. 95.
    Pickett B, Kurhanewicz J, Coakley F, et al. (2004) Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60:1047–1055PubMedGoogle Scholar
  96. 96.
    Pickett B, Ten Haken RK, Kurhanewicz J, et al. (2004) Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys 59:665–673PubMedGoogle Scholar
  97. 97.
    Barnes AS, Haker SJ, Mulkern RV, et al. (2005) Magnetic resonance spectroscopy-guided transperineal prostate biopsy and brachytherapy for recurrent prostate cancer. Urology 66:1319PubMedGoogle Scholar
  98. 98.
    Song I, Kim CK, Park BK, Park W (2010) Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. AJR Am J Roentgenol 194(6):W477–W482PubMedGoogle Scholar
  99. 99.
    Hara T, Inoue Y, Satoh T, et al. (2012) Diffusion-weighted imaging of local recurrent prostate cancer after radiation therapy: comparison with 22-core three-dimensional prostate mapping biopsy. Magn Reson Imaging 30(8):1091–1098PubMedGoogle Scholar
  100. 100.
    Kim CK, Park BK, Lee HM (2009) Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging 29:391–397PubMedGoogle Scholar
  101. 101.
    Kim CK, Park BK, Lee HM, Kim SS, Kim E (2008) MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol 190:1180–1186PubMedGoogle Scholar
  102. 102.
    Rouviere O, Girouin N, Glas L, et al. (2010) Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol 20(1):48–55Google Scholar
  103. 103.
    Vellet AD, Saliken J, Donnelly B, et al. (1997) Prostatic cryosurgery: use of MR imaging in evaluation of success and technical modifications. Radiology 203:653–659PubMedGoogle Scholar
  104. 104.
    Rouviere O, Lyonnet D, Raudrant A, et al. (2001) MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 40:265–274PubMedGoogle Scholar
  105. 105.
    Ben Cheikh A, Girouin N, Ryon-Taponnier P, et al. (2008) MR detection of local prostate cancer recurrence after transrectal high-intensity focused US treatment: preliminary results. J Radiol 89:571–577PubMedGoogle Scholar
  106. 106.
    Kirkham AP, Emberton M, Hoh IM, et al. (2008) MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology 246(3):833–844PubMedGoogle Scholar
  107. 107.
    Kalbhen CL, Hricak H, Shinohara K, et al. (1996) Prostate carcinoma: MR imaging findings after cryosurgery. Radiology 198:807–811PubMedGoogle Scholar
  108. 108.
    Cirillo S, Petracchini M, D’Urso L, et al. (2008) Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound. BJU Int 102:452–458PubMedGoogle Scholar
  109. 109.
    Donnelly SE, Donnelly BJ, Saliken JC, Raber EL, Vellet AD (2004) Prostate cancer: gadolinium-enhanced MR imaging at 3 weeks compared with needle biopsy at 6 months after cryoablation. Radiology 232:830–833PubMedGoogle Scholar
  110. 110.
    Parivar F, Hricak H, Shinohara K, et al. (1996) Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 48:594–599PubMedGoogle Scholar
  111. 111.
    Kurhanewicz J, Vigneron DB, Hricak H, et al. (1996) Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology 200:489–496PubMedGoogle Scholar
  112. 112.
    Lecouvet F, El Mouedden J, Collette L, et al. (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68–75PubMedGoogle Scholar
  113. 113.
    Wu LM, Gu H-Y, Zheng J, et al. (2011) Diagnostic value of whole-body magnetic resonance imaging for bone metastases: a systematic review and meta-analysis. J Magn Reson Imaging 34:128–135PubMedGoogle Scholar
  114. 114.
    Even-Sapir E, Metser U, Mishani E, et al. (2006) The detection of bone metastasis in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, signle- and multifield-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 47:287–297PubMedGoogle Scholar
  115. 115.
    Hövels AM, et al. (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63:387–395Google Scholar
  116. 116.
    Morris MJ, Akhurst T, Larson SM, et al. (2005) Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 11(9):3210–3216PubMedGoogle Scholar
  117. 117.
    Meirelles GSP, Schöder H, Ravizzini GC, et al. (2010) Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP Bone scan in progressing metastatic prostate cancer. Clin Cancer Res 16(24):6093–6099Google Scholar
  118. 118.
    Shreve PD, Grossman HB, Gross MD, Wahl RL (1996) Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-d-glucose. Radiology 199(3):751–756PubMedGoogle Scholar
  119. 119.
    Giovacchini G, Picchio M, Scattoni V, et al. (2010) PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 37(6):1106–1116PubMedGoogle Scholar
  120. 120.
    Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S (2011) Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol 80(2):e50–e56PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • P. J. L. De Visschere
    • 1
  • H. A. Vargas
    • 2
  • P. Ost
    • 3
  • G. O. De Meerleer
    • 3
  • G. M. Villeirs
    • 1
  1. 1.Department of RadiologyGhent University HospitalGhentBelgium
  2. 2.Department of RadiologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Department of Radiation OncologyGhent University HospitalGhentBelgium

Personalised recommendations